Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

enAsCas12a Enables CRISPR-Directed Evolution to Screen for Functional Drug Resistance Mutations in Sequences Inaccessible to SpCas9

Molecular Therapy(2020)10.1016/j.ymthe.2020.09.025Source: DataRank Database

enAsCas12a Enables CRISPR-Directed Evolution to Screen for Functional Drug Resistance Mutations in Sequences Inaccessible to SpCas9 is a research paper published in Molecular Therapy (2020). On theSindex it has a DataRank of 0. It has been cited 14 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access14 citations

Download PDF

Cite:

Linked data & code

gen pdb doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 0.75)OA: hybridTopics (66)IDs (PubMed, PMC, OpenAlex)Annotations (3)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Maarten Jacquemyn ORCID,Tim Dierckx ORCID,Benjamin P. Kleinstiver ORCID,Hendrik Jan Thibaut ORCID,Dirk Daelemans ORCID

Live enrichment

PubMed:33002419 PMC:PMC7791016 OpenAlex:https://openalex.org/W3089059445

National Institutes of Health

Grant: R00-CA218870

Damon Runyon Cancer Research Foundation

Grant: 2384-19

NCI NIH HHS

Grant: R00 CA218870

National Institutes of Health

Grant: 5R00CA218870-04

Optimizing Cancer Immunotherapy Safety and Efficacy using Genome Editing

KU Leuven

FWCI

0.75

Citation Percentile

0.7%

Citation Trend

2021

2022

2023

2024

2025

hybridLicense: cc-by-nc-nd

journalhttp://www.cell.com/article/S1525001620304822/pdf

publisherhttp://www.cell.com/article/S1525001620304822/pdf

publisherhttps://api.elsevier.com/content/article/PII:S1525001620304822?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1525001620304822?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.ymthe.2020.09.025

Fields of Study

CRISPR and Genetic EngineeringEvolution and Genetic DynamicsAdvanced biosensing and bioanalysis techniques0301 basic medicine03 medical and health sciences0303 health sciences

MeSH Terms

Binding SitesDrug ResistanceEndonucleasesGenetic TestingMutationProtein BindingClustered Regularly Interspaced Short Palindromic RepeatsCRISPR-Cas Systems

Keywords

CRISPRComputational biologyBiologyDrug resistanceGeneticsMutationNucleaseDrugGenome editingCas9Drug discoveryGeneBioinformaticsIspinesibNamptCrispr-casKif11Fk866Kpt-9274Enascas12aCrisprresCrrna TilingGENOMIC DNAINHIBITIONResearch & Experimental Medicine3105 Genetics10 TechnologyREVEALSClustered Regularly Interspaced Short Palindromic RepeatsGenetic TestingP21-ACTIVATED KINASE 411 Medical and Health SciencesGenetics & HeredityScience & TechnologyMUTAGENESISBinding SitesCHALLENGES3202 Clinical sciencesBASE06 Biological SciencesEndonucleasesENDONUCLEASETARGETBiotechnology & Applied MicrobiologyMedicine, Research & Experimental3206 Medical biotechnologyOriginal ArticleCRISPR-Cas SystemsCAS9 VARIANTSLife Sciences & BiomedicineBiotechnologyProtein Binding

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

enAsCas12a Enables CRISPR-Directed Evolution to Screen for Functional Drug Resistance Mutations in Sequences Inaccessible to SpCas9

FAIR Checklist

Authors (6)

Funding (5 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)